[Translation] A Phase Ib/II, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of IMP4297 in combination with temozolomide in patients with advanced solid tumors and small cell lung cancer
在晚期实体瘤和在接受1L含铂方案治疗后出现疾病进展的ES-SCLC患者中评估PARP抑制剂IMP4297与替莫唑胺联用的安全性、耐受性、PK特性及抗肿瘤活性。
[Translation] To evaluate the safety, tolerability, PK properties, and antitumor activity of the PARP inhibitor IMP4297 in combination with temozolomide in patients with advanced solid tumors and ES-SCLC with disease progression after 1L platinum-containing therapy.